These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35440294)

  • 1. Identifying the Physical and Mental Healthcare Needs of Opioid Treatment Program Clients.
    O'Grady MA; Neighbors CJ; Randrianarivony R; Shapiro-Luft D; Tempchin J; Perez-Cubillan Y; Collymore DC; Martin K; Heyward N; Wu M; Beacham A; Greenfield B
    Subst Use Misuse; 2022; 57(7):1164-1169. PubMed ID: 35440294
    [No Abstract]   [Full Text] [Related]  

  • 2. Together in care: Lessons learned at the intersection of integrated care, quality improvement, and implementation practice in opioid treatment programs.
    O'Grady MA; Randrianarivony R; Martin K; Perez-Cubillan Y; Collymore DC; Shapiro-Luft D; Beacham A; Heyward N; Greenfield B; Neighbors CJ
    Implement Res Pract; 2022; 3():26334895221135265. PubMed ID: 37091088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care.
    Taylor JL; Laks J; Christine PJ; Kehoe J; Evans J; Kim TW; Farrell NM; White CS; Weinstein ZM; Walley AY
    Drug Alcohol Depend; 2022 Jul; 236():109497. PubMed ID: 35607834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S.
    Wu LT; John WS; Mannelli P; Morse ED; Anderson A; Schwartz RP
    Addict Sci Clin Pract; 2023 Aug; 18(1):45. PubMed ID: 37533071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Care Integration for Hepatitis C Virus Treatment Through Facilitated Telemedicine Within Opioid Treatment Programs: Qualitative Study.
    Dickerson SS; George SJ; Ventuneac A; Dharia A; Talal AH
    J Med Internet Res; 2024 Jun; 26():e53049. PubMed ID: 38865703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U.S. Healthcare Workers' Perspective of Outpatient Provision of Methadone: A Scoping Review.
    Hernandez SE; Gilson AM; Ku TL; Gassman M; Ford JH
    Subst Use Addctn J; 2024 Oct; 45(4):753-764. PubMed ID: 39068538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to progressing through a methadone maintenance treatment programme: perspectives of the clients in the Mid-West of Ireland's drug and alcohol services.
    Moran L; Keenan E; Elmusharaf K
    BMC Health Serv Res; 2018 Nov; 18(1):911. PubMed ID: 30497467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unintended consequences of methadone regulation for opioid use disorder treatment among hospitalized patients.
    Calcaterra SL; Dafoe A; Tietbohl C; Thurman L; Bredenberg E
    J Hosp Med; 2024 Jun; 19(6):460-467. PubMed ID: 38507276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experiences of Aging with Opioid Use Disorder and Comorbidity in Opioid Treatment Programs: A Qualitative Analysis.
    Han BH; Orozco MA; Miyoshi M; Doland H; Moore AA; Jones KF
    J Gen Intern Med; 2024 Jul; 39(9):1673-1680. PubMed ID: 38436883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule.
    Laks J; Kehoe J; Farrell NM; Komaromy M; Kolodziej J; Walley AY; Taylor JL
    Addict Sci Clin Pract; 2021 Dec; 16(1):73. PubMed ID: 34961554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction of Medicare coverage in opioid treatment programs: Findings from the first three years.
    Abraham AJ; Harris SJ; Yarbrough CR
    J Subst Use Addict Treat; 2024 Mar; 158():209247. PubMed ID: 38072386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-Hospital Methadone Enrollment: a Novel Program to Facilitate Linkage from the Hospital to the Opioid Treatment Program for Vulnerable Patients with Opioid Use Disorder.
    Calcaterra SL; Saunders S; Grimm E; Maki-Gianani E; Keniston A; Wold A; Bonaguidi A
    J Gen Intern Med; 2024 Feb; 39(3):385-392. PubMed ID: 37715094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic variation in availability of opioid treatment programs across U.S. communities.
    Jehan S; Zahnd WE; Wooten NR; Seay KD
    J Addict Dis; 2024; 42(2):136-146. PubMed ID: 36645315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.
    Polydorou S; Ross S; Coleman P; Duncan L; Roxas N; Thomas A; Mendoza S; Hansen H
    Psychiatr Serv; 2017 Mar; 68(3):295-298. PubMed ID: 27745534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adapting methadone inductions to the fentanyl era.
    Buresh M; Nahvi S; Steiger S; Weinstein ZM
    J Subst Abuse Treat; 2022 Oct; 141():108832. PubMed ID: 35870437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of random and observed urine drug screening with long-term retention in opioid treatment programs.
    Michener PS; Knee A; Wilson D; Boama-Nyarko E; Friedmann PD
    Drug Alcohol Depend; 2024 Feb; 255():111067. PubMed ID: 38183832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender disparities in access and retention in outpatient methadone treatment for opioid use disorder in low-income urban communities.
    Marsh JC; Amaro H; Kong Y; Khachikian T; Guerrero E
    J Subst Abuse Treat; 2021 Aug; 127():108399. PubMed ID: 34134873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets.
    Amiri S; Hirchak K; Lutz R; McDonell MG; McPherson SM; Roll JM; Amram O
    Drug Alcohol Depend; 2018 Dec; 193():63-68. PubMed ID: 30340146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.